title: [Results of treatment of osteosarcoma in children according to the SFOP-94 protocol in the experience of the Polish Paediatric Solid Tumour Study Group].
abstract: Between April 1994 and December 1999, 34 children aged from 5 to 20 years (23 females and 11 males) suffering from osteosarcoma, were treated according to the SFOP-94 protocol. The primary preoperative chemotherapy consists of adriamycin and high-dose methotrexate administration. There were 28 patients with non-metastatic tumours of the extremities and 6 children presented disseminated disease with pulmonary metastases. The primary localization included femur - 20 patients, tibia - 9 patients and humerus - 5 patients. In 26 patients limb-salvage surgery was applied. The programme of chemotherapy was changed in 4 children because of toxicity of methotrexate (1 patient) and progression of disease (3 patients). 26 out of 34 (76,5 %) children are alive including 24 out of 28 patients with localized disease. EFS calculated according to Kaplan-Meier analysis was 60 % at 67 months.
authors.affiliation: Klinika Hematologii i Chorób Rozrostowych Akademia Medyczna we Wrocławiu, ul. Bujwida 44, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: W
authors.initials: W
authors.lastname: Jaworski
authors.forename: M
authors.initials: M
authors.lastname: Liebhart
authors.forename: W
authors.initials: W
authors.lastname: Gołebiowski
authors.forename: B
authors.initials: B
authors.lastname: Kazanowska
authors.forename: J
authors.initials: J
authors.lastname: Wecławek-Tompol
authors.forename: W
authors.initials: W
authors.lastname: Woźniak
authors.forename: J
authors.initials: J
authors.lastname: Kijowski
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: K
authors.initials: K
authors.lastname: Katski
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: D
authors.initials: D
authors.lastname: Boruczkowski
authors.forename: M
authors.initials: M
authors.lastname: Leda
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005269:Femur / Q000473:pathology; D006801:Humans; D006811:Humerus / Q000473:pathology; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology; D011044:Poland; D012074:Remission Induction; D012189:Retrospective Studies; D013977:Tibia / Q000473:pathology; D013997:Time Factors
chemical_list: D004317:Doxorubicin; D008727:Methotrexate